Device Sectors
Heart patients with anxiety disorder experience more cardiovascular events, deaths
July 5, 2010 3:36 pm | by EurekAlert | News | Comments(JAMA and Archives Journals) Among patients with heart disease, anxiety disorders appear to be associated with a higher risk of stroke, heart attack, heart failure and death, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
FDA Approves Strativa Pharmaceuticals' Zuplenz® (ondansetron) Oral Soluble Film
July 2, 2010 8:36 pm | by Bio-Medicine.Org | News | CommentsWOODCLIFF LAKE, N.J. , July 2 /- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and...
MiMedx Group, Inc. Announces Release Date for Second Quarter Results
July 2, 2010 11:36 am | by Bio-Medicine.Org | News | CommentsMARIETTA, Ga. , July 2 /- MiMedx Group, Inc. (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that its results for the second quarter, ended June 30, 2010 , will be released before the opening of...
Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
July 2, 2010 11:36 am | by Bio-Medicine.Org | News | CommentsMORRISTOWN, N.J. , July 2 /- Watson Pharmaceuticals, Inc. (NYSE: WPI ) today completed the acquisition of the U.S. rights to Columbia Laboratories' CRINONE® and PROCHIEVE® progesterone gel product line and 11,200,000 shares of Columbia common stock. "We are pleased to add...
Spina bifida topic of monthly genetics series
July 2, 2010 7:32 am | by Baylor College of Medicine | News | CommentsSpina bifida, a birth defect that involves the incomplete development of the spinal cord, will be the topic of discussion in a public forum Wednesday, July 14, at The Health Museum of Houston . The forum will feature Dr. Daryl Scott, assistant professor of molecular and human genetics at...
Breast Cancer Patient First in Latin America to Receive Treatment Using Elekta VMAT Planned with Monaco Software
July 2, 2010 6:35 am | by Bio-Medicine.Org | News | CommentsMONTERREY, Mexico and ATLANTA , July 2 /- A 64-year-old female patient with mediastinal metastasis recently became the first in Latin America to receive Elekta VMAT radiotherapy treatment enhanced with Monaco® planning software . Using the arc-based Elekta VMAT delivery method,...
Watson's Generic Prograf® 5 mg Receives FDA Approval
July 2, 2010 6:33 am | by Bio-Medicine.Org | News | CommentsMORRISTOWN, N.J. , July 2 /- Watson Pharmaceuticals, Inc. (NYSE: WPI ), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules,...
Yale spin-off Mira Dx gets $1M from Conn. state fund
July 2, 2010 5:32 am | by Mass High Tech: The Journal of New England Technology | News | CommentsMira Dx Inc., a New Haven, Conn., startup that is making gene-based lab tests for disease susceptibility and response to various therapies, has taken in $1 million from Connecticut Innovations, as part of a $4 million Series A round.
China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2010 on August 16, 2010
July 2, 2010 3:34 am | by Bio-Medicine.Org | News | CommentsBEIJING , July 2 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China -based advanced in-vitro diagnostic ("IVD") company, today announced that it will report its unaudited financial results for the first fiscal quarter ("1Q...
Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinson's Disease
July 1, 2010 11:33 am | by Bio-Medicine.Org | News | CommentsRICHMOND, Calif. , July 1 /- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that it has been awarded a second round of funding by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support studies in non-human primates for the development of a ZFP...
Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
July 1, 2010 11:33 am | by Bio-Medicine.Org | News | CommentsJames E. Connolly Committed to Accelerating the Development of New Vaccines to Prevent Tuberculosis ROCKVILLE, Md. , July 1 /PRNewswire-USNewswire/ -- The Aeras Global TB Vaccine Foundation today announced that James E. Connolly has been named President and Chief Executive Officer....
Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
July 1, 2010 11:33 am | by Bio-Medicine.Org | News | CommentsBEIJING , July 1 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China , said today that Rita Zheng Liu , Chief Financial Officer, and Sam...
PartsSource Wins 2010 Venture of the Year Award
July 1, 2010 11:33 am | by Bio-Medicine.Org | News | CommentsAURORA, Ohio , July 1 /- PartsSource, the world's #1 eBusiness Solution provider for replacement medical repair parts for hospital equipment, has been honored with the 2010 Venture of the Year Award for Northern Ohio . The Ohio Venture Association is a group of northeast Ohio...
China PharmaHub Corp. Enters Into Definitive Agreement for Humanized Antibody
July 1, 2010 11:32 am | by Bio-Medicine.Org | News | CommentsBOSTON , July 1 /- China PharmaHub Corp. ("PharmaHub"), announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz . In addition, PharmaHub contemplates merging with World Wide Relics, Inc. (OTC Bulletin Board: WRLC) of which it...
Targegen Acquisition Could Be Worth as Much as $560M
July 1, 2010 11:32 am | by San Diego Business Journal | News | CommentsTargegen Inc., a San Diego biotech developing a drug to treat blood diseases, agreed to be acquired by Sanofi-Aventis, a French public company for what could be $560 million if the company reaches certain milestones.
Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators
July 1, 2010 9:33 am | by EurekAlert | News | Comments(Damon Runyon Cancer Research Foundation) The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its April 2010 Clinical Investigator Award Committee review. The recipients of this prestigious three-year award are outstanding early career...
Sysmex America Announces Executive Leadership Changes
July 1, 2010 9:33 am | by Bio-Medicine.Org | News | CommentsMUNDELEIN, Ill. , July 1 /- Sysmex America Inc., a leading medical diagnostic instrument manufacturer and information systems developer, today announces executive changes in the areas of corporate affairs, operations and technical services. John Kershaw, President & CEO, Sysmex...
Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
July 1, 2010 8:34 am | by Bio-Medicine.Org | News | CommentsMORRISTOWN, N.J. , July 1 /- Watson Pharmaceuticals, Inc. (NYSE: WPI ) today confirmed that shareholders of Columbia Laboratories, Inc. (Nasdaq: CBRX ) have approved the terms and conditions of the previously announced acquisition by Watson of the U.S. rights to Columbia 's CRINONE®...
Watson Launches Generic Exelon®
July 1, 2010 8:34 am | by Bio-Medicine.Org | News | CommentsMORRISTOWN, N.J. , July 1 /- Watson Pharmaceuticals, Inc. (NYSE: WPI ) announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has...
Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion
July 1, 2010 8:34 am | by Bio-Medicine.Org | News | CommentsATLANTA , July 1 /- The refinements in Elekta's Gamma Knife ® surgery technology that created the fifth generation Leksell Gamma Knife® Perfexion™ are radically changing the approach to treating brain metastases and other brain disorders. With Perfexion, physicians are...
NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
July 1, 2010 8:34 am | by Bio-Medicine.Org | News | CommentsNEW YORK , July 1 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China , today announced that it has appointed Roberto Bolli , M.D., to its Scientific Advisory Board....
FUISZ Announces Advances in Devices and Solid Dosage Form
July 1, 2010 5:35 am | by Bio-Medicine.Org | News | CommentsMIAMI , July 1 /- FUISZ today announced two medical technology advances. First, FUISZ announced that it has received a notice of issuance from the United States Patent and Trademark Office for patent claims that cover a direct connection between prescribing physicians and blood analysis...
Par Pharmaceutical Begins Shipment of Generic Zegerid®
July 1, 2010 5:35 am | by Bio-Medicine.Org | News | CommentsWOODCLIFF LAKE, N.J. , July 1 /- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that it began shipping the 20mg/1100mg and 40mg/1100mg strengths of omeprazole and sodium bicarbonate capsules to the trade. Omeprazole and sodium bicarbonate capsules are the generic version...
FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP
July 1, 2010 5:35 am | by Bio-Medicine.Org | News | CommentsSCHAUMBURG, Ill. , July 1 /- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's nine presentations of heparin sodium injection, USP. Heparin is a vital anticoagulant,...
Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology
July 1, 2010 5:33 am | by IBM | News | CommentsYORKTOWN HEIGHTS, N.Y. and BRANFORD, Conn., July 1 /PRNewswire-FirstCall/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and IBM (NYSE: IBM) announced today an agreement to develop a nanopore-based technology that will directly read and sequence human DNA quickly and efficiently. Focused on...
